Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
3.060
+0.170 (5.88%)
At close: Apr 28, 2026, 4:00 PM EDT
3.050
-0.010 (-0.33%)
After-hours: Apr 28, 2026, 5:20 PM EDT
Editas Medicine Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 40.52 | 32.31 | 78.12 | 19.71 | 25.54 | |
| Revenue Growth (YoY) | 25.39% | -58.64% | 296.32% | -22.83% | -71.85% | |
| Cost of Revenue | 89.95 | 199.25 | 177.65 | 174.96 | 142.51 | |
| Gross Profit | -49.43 | -166.93 | -99.53 | -155.25 | -116.96 | |
| Selling, General & Admin | 49.9 | 71.99 | 69.65 | 70.7 | 76.18 | |
| Operating Expenses | 49.9 | 71.99 | 69.65 | 70.7 | 76.18 | |
| Operating Income | -99.34 | -238.92 | -169.18 | -225.95 | -193.15 | |
| Interest Expense | -6.17 | -2.19 | - | - | - | |
| Interest & Investment Income | 8.31 | 16.25 | 17.57 | 5.52 | 0.61 | |
| Other Non Operating Income (Expenses) | - | - | - | - | 0.04 | |
| EBT Excluding Unusual Items | -97.2 | -224.86 | -151.62 | -220.43 | -192.5 | |
| Merger & Restructuring Charges | -56.92 | -12.23 | - | - | - | |
| Gain (Loss) on Sale of Investments | -2.19 | -0 | -1.6 | - | - | |
| Gain (Loss) on Sale of Assets | -3.76 | - | - | - | - | |
| Pretax Income | -160.06 | -237.09 | -153.22 | -220.43 | -192.5 | |
| Net Income | -160.06 | -237.09 | -153.22 | -220.43 | -192.5 | |
| Net Income to Common | -160.06 | -237.09 | -153.22 | -220.43 | -192.5 | |
| Shares Outstanding (Basic) | 89 | 82 | 76 | 69 | 68 | |
| Shares Outstanding (Diluted) | 89 | 82 | 76 | 69 | 68 | |
| Shares Change (YoY) | 7.78% | 8.39% | 10.63% | 1.55% | 15.37% | |
| EPS (Basic) | -1.80 | -2.88 | -2.02 | -3.21 | -2.85 | |
| EPS (Diluted) | -1.80 | -2.88 | -2.02 | -3.21 | -2.85 | |
| Free Cash Flow | -165.85 | -219.11 | -136.9 | -181.47 | -171.78 | |
| Free Cash Flow Per Share | -1.87 | -2.66 | -1.80 | -2.64 | -2.54 | |
| Gross Margin | -122.00% | - | -127.40% | - | - | |
| Operating Margin | -245.15% | -739.37% | -216.56% | -1146.26% | -756.13% | |
| Profit Margin | -395.01% | -733.72% | -196.13% | -1118.26% | -753.61% | |
| Free Cash Flow Margin | -409.30% | -678.06% | -175.23% | -920.59% | -672.49% | |
| EBITDA | -94.06 | -233.11 | -163.12 | -219.61 | -188.09 | |
| EBITDA Margin | -232.13% | - | -208.80% | - | - | |
| D&A For EBITDA | 5.28 | 5.81 | 6.06 | 6.34 | 5.05 | |
| EBIT | -99.34 | -238.92 | -169.18 | -225.95 | -193.15 | |
| EBIT Margin | -245.15% | - | -216.56% | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.